KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer

BACKGROUND: KRAS mutations are predictive markers for the efficacy of anti-EGFR antibody therapies in patients with metastatic colorectal cancer. Although the mutational status of KRAS is reportedly highly concordant between primary and metastatic lesions, it is not yet clear whether genotoxic chemo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kawamoto, Y, Tsuchihara, K, Yoshino, T, Ogasawara, N, Kojima, M, Takahashi, M, Ochiai, A, Bando, H, Fuse, N, Tahara, M, Doi, T, Esumi, H, Komatsu, Y, Ohtsu, A
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2012
Assuntos:
Molecular Diagnostics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3394966/
https://ncbi.nlm.nih.gov/pubmed/22617127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.218
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares